CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.